North of England evidence based development project: Guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure

BMJ

Volumn 316, Issue 7141, 1998, Pages 1369-

  Eccles, Martin ^a   Freemantle, Nick ^a   Mason, James ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RADIOISOTOPE; RAMIPRIL; SPIRAPRIL;

COST EFFECTIVENESS ANALYSIS; COUGHING; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNITED KINGDOM;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; COST-BENEFIT ANALYSIS; DECISION MAKING; DIURETICS; ECHOCARDIOGRAPHY; HUMANS; HYPERKALEMIA; HYPOTENSION; MYOCARDIAL INFARCTION; QUALITY OF LIFE; RISK FACTORS;

EID: 0032474275     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7141.1369     Document Type: Article

References (67)

1. Eccles M. Freemantle N. Mason J. North of England Evidence-Based Guidelines Development Project: methods of developing guidelines for efficient drug use in primary care. BMJ 1998;316:1232-1235.
2. North of England Evidence-Based Guideline Development Project. Evidence-based clinical practice guideline: ACE-inhibitors in the primary care management of adults with heart failure. Centre for Health Services Research University of Newcastle upon Tyne and Centre for Health Economics, University of York, 1997.
3. McCormick A. Fleming D. Charlton J. Morbidity statistics in general practice: fourth national study 1991-1992. London: HMSO, 1995(Series M.B. No 3.)
4. Mair F.S. Carowley T.S. Bundred P.K. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996;46:77-79.
5. McMurray J. Hart W. Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK Br J Med Econ 1993;6:99-110.
6. Wheeldon N.M. MacDonald T.M. Flucker C.J. McKendrick A.D. McDevitt D.G. Struthers A.D. Echocardiography in chronic heart failure in the community. Q J Med 1993;86:17-23.
7. Parameshwar J. Shackell M.M. Richardson A. Poole-Wilson P.A. Sutton G.C. Prevalence of heart failure in three general practices in north west London. Br J Gen Pract 1992;42:287-289.
8. Department of Health. Hospital episode statistics, 1993-4. London: Department of Health, 1995.
9. Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741-751.
10. Clark K.W. Gray D. Hampton J.R. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994;71:584-587.
11. Remes J. Miettinen H. Reunanen A. Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-321.
12. Garg R. Yusuf S. Overview of randomized trials of ACE-inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-1456.
13. Colfer H.T. Ribner H.S. Gradman A. Hughes V. Kapoor A. Laideau JC for the Benazepril Heart Failure Study Group. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am J Cardiol 1992;70:354-358.
14. McGarry R. Randomized, double blind, multicentre study comparing benazepril to digoxin and to placebo as add on therapy to diuretic in patients with CHF, NYHA class II-III during a 12 week treatment period, GHBA-194. Summit, NJ Ciba-Geigy Pharmaceuticals, 1991.
15. Magnani B. Magelli C for the Multicentre Research Group on Mild Heart Failure. Captopril in mild heart failure: preliminary observations of a long-term double-blind, placebo-controlled multicentre trial. Postgrad Med J 1986; 62 (suppl B): 153-158.
16. Bussmann W.D. Storger H. Hadler D. Reifart N. Fassbinder W. Jungmann E et al. Long-term treatment of severe chronic heart failure with captopril: a double-blind randomized, placebo-controlled long-term study. J Cardiovasc Pharmacol 1987; 9 (suppl 2): S50-S60.
17. Captopril-Digoxin Multicentre Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-544.
18. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-763.
19. Barabino A. Galbariggi G. Pizzorni C. Lotti G. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology 1991;78:289-296.
20. Kleber F.X. Niemoller L. Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich mild heart failure trial. Br Heart J 1992;67:289-296.
21. Drexler H. Banhardt B.S. Meinertz T. Wollschlager H. Lehmann M. Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure: a double blind, placebo controlled trial. Circulation 1989;79:491-502.
22. Cleland J.G.F. Dargie H.J. Ball S.G. Gillen G. Hodsman G.P. Morton JJ et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones and metabolic state. Br Heart J 1985;54:305-311.
23. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
24. Enalapril C.H. Investigators. Long-term effects of enalapril in patients with congestive heart failure: a multicentre, placebo-controlled trial. Heart Failure 1987;3:102-107.
25. Dickstein K. Barvik S. Aarsland T. Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction. J Am Coll Cardiol 1991;18:596-602.
26. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
27. Rucinska E.J. A double blind placebo controlled study to evaluate the effects of enalapril in patients with chronic heart failure. West Point, PA Merck Sharpe & Dohme, 1991.
28. Rucinska E.J. Enalapril vs placebo in previously untreated patients with CHF. West Point, PA Merck Sharpe & Dohme, 1991.
29. Zwehl W. Rucinska E for the Lisinopril Chronic Heart Failure Investigators. Long-term effects of lisinopril in patients with chronic heart failure: a multicentre, placebo-controlled trial. In: Ed. Nicholls MG ed. A focus on the clinical effects of a long acting ACE-inhibitor in heart failure., New York: Raven, 1990:3140.
30. Giles TD for Lisinopril Chronic Heart Failure Group. Lisinopril treatment of congestive heart failure results of a placebo controlled trial. Circulation 1990; 82: 323.
31. Gilbert E.M. Sandoval A. Larabee P. Renlund D. O'Connell J.B. Bristow M.R. Lisinopril lowers cardiac adrenergic drive and increases B-receptor density in the failing human heart. Circulation 1993;88:472-480.
32. Ruckinska E.J. Lisinopril first line therapy in CHF. West Point, PA Merck Sharpe & Dohme, 1991.
33. Lechat P. Garnham J. Desche P. Bounhoure J.P. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993;126:798-806.
34. Riegger GAJ. The effects of ACE-inhibitors on exercise capacity in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1990; 15 (suppl 2): 41-46.
35. Northridge D.B. Rose E. Elder A. Raftery E.D. Lahiri A. Elder A.T. Shaw T.R.D. et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild chronic heart failure. Eur Heart J 1993;14:403-409.
36. Uprichard A. A 16-week double blind, placebo-randomized, placebo controlled multicentre trial to evaluate the effects of withdrawal of quinapril hydrochloride on exercise tolerance in patients with mild to moderate congestive heart failure (906-276). Ann Arbour, MI Parke-Davis Pharmaceutical Research, 1994.
37. Uprichard A. An 18-week double blind, optional titration, multicentre study to compare the efficacy and safety of orally administered quinapril hydrochloride with captopril and placebo in patients with congestive heart failure (906-226). Ann Arbour, MI Parke-Davis Pharmaceutical Research, 1994.
38. Uprichard A. A 12-week double blind, placebo controlled study to determine the efficacy and safety of orally administered quinapril hydrochloride in patients with congestive heart failure (906-63). Ann Arbour, MI Parke-Davis Pharmaceutical Research, 1994.
39. Swedberg K. Amtorp O. Gundersen T. Remes J. Nilsson B. Is maximal exercise testing a useful method to evaluate treatment of moderate heart failure [abstract]? Circulation 1991; 57: 226.
40. Maass L. Double blind comparative trial with ramipril and placebo in patients with heart failure (NYHA class III-IV) stabilised on digitalis and frusemides. Frankfurt: Hoechst, 1991.
41. Gordon M. Evaluation of the efficacy and safety of ramipril (HOE 498) in patients with congestive heart failure in a placebo-controlled trial. Somerville, NJ Hoechst-Roussel Pharmaceuticals, 1991.
42. Maass L. Efficacy and safety of ramipril (HOE 498) in patients with congestive heart failure in a double blind placebo controlled trial. Frankfurt: Hoechst, 1991.
43. Maass L. Evaluation of the effect of ramipril (HOE 498) on exercise duration, invasive cardiac haemodynamics profiles and safety in patients with congestive heart failure. Frankfurt: Hoechst, 1991.
44. Lemarie J.C. Multicentre double blind placebo controlled study of the efficacy and safety of ramipril administered orally for 24 weeks in the treatment of stable chronic congestive cardiac failure. Paris: Hoechst, 1992.
45. Keren G. Pardes A. Eschar Y. Hansch E. Scherez J. Laniado S. Left ventricular filling dynamics by doppler echocardiography in dilated cardiomyopathy: one-year follow up in patients treated with captopril compared to placebo. Cardiology 1992;81:196-206.
46. Cilazapril-Captopril Multicentre Group. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double blind, randomized multicenter trial. Cardiology 1995; 86 (suppl 1): 34-40.
47. De Bock V. Mets T. Romagnoli M. Derde M.P. Captopril treatment of chronic heart failure in the very old. J Gerontol 1994;49:M148-M152.
48. Dossegger L. Aldor E. Baird M.G. Braun S. Cleland J.G.F. Donaldson R et al. Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial. Eur Heart J 1993; 14 (suppl C): 18-19.
49. Nicholls M.G. Ikram H. Espiner E.A. Webster MWI, Fitzpatrick M.A. Enalapril in heart failure. Br J Clin Pharmacol 1984;18:163-167 S.
50. Brown E.J. Chew P.H. MacLean A. Gelperin K. Ilgenfritz J.P. Blumethal M for the Fosinopril Heart Failure Study Group. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol 1995;75:596-600.
51. Widimsky J. Kremer H.J. Jerie P. Uhlir O for the CASSIS investigators. Czech and Slovak spirapril intervention study (CASSIS): a randomized, placebo and active-controlled, double-blind muticentre trial in patients with congestive heart failure. Eur J Clin Pharmacol 1995;49:95-102.
52. Karrison T.G. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups—interpretation and power considerations. Controlled Clin Trials 1997;18:151-167.
53. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
54. Galcera-Tomas J. Antonio Nuno de la Roas J. Torres-Martinez G. Rodriguez-Garcia P. Castillo-Soria F.J. Canton-Martinez A. et al. Effects of early use of captopril on haemodynamics and short term ventricular remodelling in acute anterior myocardial infarction. Eur Heart J 1993;14:259-266.
55. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
56. Pfeffer M.A. Branunwald E. Moy L.A. Basta L. Brown E.J. Cuddy TE et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
57. Kober L. Torp-Pedersen C. Carlesen J.E. Bagger H. Eliasen P. Lyngborg K. et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clincal trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1676.
58. Narang R. Swedberg K. Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE-inhibitors on exercise capacity. Eur Heart J 1996;17:120-134.
59. Rogers W.J. Johnstone D.E. Yusuf S. Weiner D.H. Gallagher P. Bittner VA et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol 1994;23:393-400.
60. Pouleur H. ACE-inhibitors in the treatment of clinical heart failure. Basic Res Cardiol 1993; 88 (suppl 1): 203-209.
61. British national formulary. No 32. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1996.
62. Agency for Health Care Policy and Research. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Rockville, MD Agency for Health Care Policy and Research, 1994(Clinical practice guideline 11.)
63. Frank G.J. The safety of ACE-inhibitors for the treatment of hypertension and congestive heart failure. Cardiology 1989; 76 (suppl 2): 56-57.
64. O'Neill C.J. Bowes S.G. Sullens C.M. Royston J.P. Hunt W.B. Denham MJ et al. Evaluation of the safety of enalapril in the treatment of heart failure in the very old. Eur J Clin Pharmacol 1988; 35:143-150.
65. Department of Health, Office of Population Censuses and Surveys. The government's expenditure plans 1994-95 to 1996-97. London: HMSO, 1994.
66. Chartered Institute of Public Finance and Accountancy, Healthcare Financial Management Association. The health service financial database 1997 [CD ROM]. London: CIPFA, 1997.
67. Netten A. Dennett S. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Canterbury, 1997.